More on Supernus Pharmaceuticals earnings

• Supernus Pharmaceuticals (NASDAQ:SUPN) Q2 EPS loss comes in greater than anticipated.
• EPS -46% from the same quarter last year.
• Net product revenue of $200K, which is comprised of 529 Oxtellar XRTM prescriptions filled at the pharmacy level, with the net price of Oxtellar XR reflecting deductions for one-time discounts paid to wholesalers, as well as customary payer rebates, allowances, and the cost of a co-payment rebate program.
• Gross margin on net product revenue was 97%.